StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) company profile

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.18+0.00 (+2.11%)

Close on Nov 16, 2026Market cap $8.18MP/E –Yield –

About Vistagen Therapeutics

Pharmaceutical Preparations, SIC 2834

Vistagen is a late clinical-stage biotechnology company engaged in the research, development, and potential commercialization of novel treatments for central nervous system and women's health conditions. The company's pipeline centers on intranasal pherine product candidates designed with a non-systemic neurocircuitry-focused mechanism of action. Its drug candidates include fasedienol for social anxiety disorder, itruvone for major depressive disorder, refisolone for menopausal vasomotor symptoms and premenstrual dysphoric disorder, PH15 for cognitive and psychomotor impairment caused by mental fatigue, and PH284 for cancer cachexia. The company also investigates AV-101, an oral prodrug targeting neurological conditions. Its target population comprises patients experiencing these severe conditions, including individuals suffering from social phobias, depression, and menopausal hot flashes.

The company conducts clinical development programs primarily within the United States and has performed exploratory clinical studies in Mexico. It also maintains intellectual property portfolios across domestic and foreign markets, holding granted patents and pending applications in the United States and international jurisdictions such as Europe and Japan.

Summary of the business section of Vistagen Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Vistagen Therapeutics, Inc.
Headquarters
South San Francisco, CA
Address
343 Allerton Avenue 94080
Phone
(650) 577-3600
Employees
41, Mar 31, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
March 31
Auditor
KPMG LLP, San Francisco, California

Stock & identifiers

Ticker
VTGN
Former tickers
VSTA until Jun 24, 2016
Exchange
Nasdaq
IPO date
Jun 21, 2011
Shares outstanding
44M, Aug 10, 2026
Public float
$137.70M, Sep 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-30 reverse, Jun 7, 2023; 1-for-20 reverse, Aug 14, 2014
SEC CIK
1411685
CUSIP
92840H400
ISIN
US92840H4002
FIGI
BBG000BB33L9
Share class FIGI
BBG001S67BH3
EIN
20-5093315

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Shawn SinghPresident and CEO, Director75,721
Nick B. TresslerChief Financial Officer11,712
Reid G. AdlerChief Legal Officer60,868
Angel S. AngelovChief Medical Officer–
Joshua S. PrinceChief Operating Officer15,249
Elissa S. CoteChief Corp Development Officer–
Cynthia Lynn AndersonCHIEF FINANCIAL OFFICER12,801
Douglas J. WilliamsonDirector–
Paul R. EdickDirector–
Joanne CurleyDirector–
Mary L. RotunnoDirector–
Ann Michelle CunninghamDirector–
Jon S. SaxeDirector55,751
Margaret M. FitzPatrickDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$1.21M$132.45K$700.67K$2–
FY2025$2.48M$2.06M$1.11M$7–
FY2024$947.92K$1.18M$559.21K$8–
FY2023$600.00K$225.35K$493.41K$6–
FY2022$1.18M-$371.53K$356.06K$58–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Shawn K. Singh, J.D.
President, Chief Executive Officer and Director
$650.00K–$562.56K–$1.21M-51%
Nick B. Tressler, MBA
Chief Financial Officer and Treasurer
$150.00K$50.00K$641.79K$24.73K$866.52K–
Reid G. Adler, J.D.
Chief Legal Officer
$450.00K–$187.52K–$637.52K-46%
Elissa S. Cote
Chief Corporate Development and Strategy Officer
$320.68K$35.00K$281.93K$58.53K$696.13K–
Joshua S. Prince, MBA
Chief Operating Officer
$415.00K–$187.52K–$602.52K-43%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 31, 2026, we employed 41 full-time employees; 30 full-time employees work in research and development and laboratory support services, and 11 full-time employees work in management, corporate development and communications, legal, human resources, and other general and administrative roles.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 5, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 2, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 6, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 12, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 7, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 21, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 13, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 3, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 31, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 23, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 21, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 15, 2016Late filingNotification of late filing
May 3, 2016ListingRegistration of securities on an exchange (Form 8-A)
Nov 14, 2014Late filingNotification of late filing
Jul 1, 2013Late filingNotification of late filing
Jun 29, 2012Late filingNotification of late filing
Dec 20, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 16, 2011Late filingNotification of late filing
Aug 12, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 8, 2011Name changeName changed from Excaliber Enterprises, Ltd. to Vistagen Therapeutics, Inc.
Jun 8, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 8, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
May 16, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
May 16, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?